C R Bard (BCR) Earns Media Impact Rating of 0.32
News articles about C R Bard (NYSE:BCR) have been trending positive this week, Accern reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. C R Bard earned a coverage optimism score of 0.32 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 45.3317861877906 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- Kellner Capital Has Increased Cr Bard (BCR) Stake By $6.46 Million; Aceto (ACET) Shorts Down By 11.99% – Hill Country Times (hillcountrytimes.com)
- CR Bard, Inc. (BCR) folded -0.51% down SMA-20 – The Stocks News (press release) (thestocksnews.com)
- C.R. Bard, Inc. — Moody’s withdraws C.R. Bard’s ratings (finance.yahoo.com)
- BD And Bard Expect Proposed Acquisition To Close On Dec. 29 – Markets Insider (markets.businessinsider.com)
- CR Bard, Inc. (NYSE:BCR) – Track P/E Before Buying A Stock – Nasdaq Journal (press release) (nasdaqjournal.com)
A number of equities research analysts recently issued reports on BCR shares. Zacks Investment Research raised C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price target on the stock in a research report on Tuesday, December 26th. ValuEngine downgraded C R Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Barclays increased their price target on C R Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research report on Monday, November 6th. Jefferies Group reissued a “hold” rating and set a $317.00 price target on shares of C R Bard in a research report on Thursday, September 14th. Finally, Cowen reissued a “hold” rating and set a $317.00 price target on shares of C R Bard in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. C R Bard presently has a consensus rating of “Hold” and a consensus price target of $305.00.
Shares of C R Bard (BCR) traded down $1.95 during mid-day trading on Wednesday, hitting $331.24. The company’s stock had a trading volume of 4,714,800 shares, compared to its average volume of 679,456. The firm has a market cap of $24,140.00, a P/E ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52. C R Bard has a 52-week low of $222.42 and a 52-week high of $337.73. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72.
C R Bard (NYSE:BCR) last issued its earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.96 by $0.06. The firm had revenue of $989.80 million for the quarter, compared to the consensus estimate of $990.64 million. C R Bard had a return on equity of 19.39% and a net margin of 9.51%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.64 EPS. analysts expect that C R Bard will post 11.89 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, December 29th. Shareholders of record on Friday, December 8th were issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.31%. The ex-dividend date of this dividend was Thursday, December 7th. C R Bard’s dividend payout ratio is presently 10.28%.
In other news, insider Timothy P. Collins sold 8,388 shares of the stock in a transaction on Monday, October 9th. The stock was sold at an average price of $322.00, for a total value of $2,700,936.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Timothy P. Collins sold 55,818 shares of the stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $322.03, for a total value of $17,975,070.54. The disclosure for this sale can be found here. In the last ninety days, insiders sold 193,887 shares of company stock worth $63,801,024. Company insiders own 0.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.dailypolitical.com/2018/01/03/c-r-bard-bcr-earns-media-impact-rating-of-0-32.html.
About C R Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.